Bingham Osborn & Scarborough’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bingham Osborn & Scarborough’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-15,436	Closed	-$2.2M	–	153
2020 Q3	$2.2M	Hold	15,436	–	–	0.17%	38
2020 Q2	$1.7M	Buy	15,436 +24	+0.2%	+$2.65K	0.14%	43
2020 Q1	$1.54M	Hold	15,412	–	–	0.15%	41
2019 Q4	$2.3M	Hold	15,412	–	–	0.19%	35
2019 Q3	$1.98M	Hold	15,412	–	–	0.18%	36
2019 Q2	$2.2M	Hold	15,412	–	–	0.2%	33
2019 Q1	$2.2M	Hold	15,412	–	–	0.2%	32
2018 Q4	$1.91M	Hold	15,412	–	–	0.19%	34
2018 Q3	$2.59M	Hold	15,412	–	–	0.23%	33
2018 Q2	$2.65M	Hold	15,412	–	–	0.25%	31
2018 Q1	$2.33M	Hold	15,412	–	–	0.22%	33
2017 Q4	$2.08M	Hold	15,412	–	–	0.19%	32
2017 Q3	$2.25M	Hold	15,412	–	–	0.21%	30
2017 Q2	$2.4M	Hold	15,412	–	–	0.23%	28
2017 Q1	$2.24M	Hold	15,412	–	–	0.22%	28
2016 Q4	$1.68M	Hold	15,412	–	–	0.18%	31
2016 Q3	$1.87M	Hold	15,412	–	–	0.2%	31
2016 Q2	$2.18M	Hold	15,412	–	–	0.25%	30
2016 Q1	$2.01M	Hold	15,412	–	–	0.23%	30
2015 Q4	$2.17M	Hold	15,412	–	–	0.26%	29
2015 Q3	$2.05M	Hold	15,412	–	–	0.26%	28
2015 Q2	$2.71M	Sell	15,412 -1,471	-9%	-$264K	0.33%	24
2015 Q1	$2.92M	Hold	16,883	–	–	0.35%	23
2014 Q4	$2.76M	Hold	16,883	–	–	0.33%	26
2014 Q3	$2.71M	Buy	+16,883	New	+$2.6M	0.34%	25

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bingham Osborn & Scarborough's JAZZ Position: Q4 2020 in Review

Bingham Osborn & Scarborough sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2020, closing a stake of 15,436 shares — an estimated $2.2M sold.

Bingham Osborn & Scarborough first reported a position in JAZZ in Q3 2014 and held it in 25 quarters. The position peaked at $2.92M in Q1 2015. 437 funds tracked by Wall St. Rank hold JAZZ as of Q4 2020.

Bingham Osborn & Scarborough reported no remaining Jazz Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Bingham Osborn & Scarborough sold 15,436 Jazz Pharmaceuticals shares in Q4 2020, an estimated $2.2M.
Bingham Osborn & Scarborough first reported a position in Jazz Pharmaceuticals in Q3 2014 and held it in 25 quarters.
Bingham Osborn & Scarborough's Jazz Pharmaceuticals position peaked at $2.92M in Q1 2015.
437 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2020.

Based on Bingham Osborn & Scarborough's 13F filing for Q4 2020, filed 11 Feb 2021.